Femtech Insider

🚀 Virtual #menopause care clinic Midi Health has expanded its services to include #testosterone hormone therapy for women, responding to demand from its patient base. The company now offers the treatment in 12 states, with plans for nationwide expansion as state regulations permit. The service provides access to a topical cream formulation designed for women, delivered through clinician-led care with personalized dosing. 👩⚕️ 💬 “The fact there’s still no FDA-approved option for women in the U.S. is a glaring inequity that leaves millions suffering in silence. Our offering provides ongoing care from clinicians who personalize treatment plans and check in regularly to ensure women are getting the results and support they need, all while being covered by insurance.” Joanna Strober, Co-founder & CEO of Midi Health 👉 Full story: https://lnkd.in/ggptV3Pq #femtech #womenshealth #womenshealthinnovation #telehealth #virtualcare #digitalhealth #menopause #midlife #hormonehealth

💰 Swiss medtech startup MoleSense has received €156,000 (CHF 150,000) from Venture Kick to develop wearables that monitor inflammatory proteins and steroid hormones through sweat analysis in high-risk pregnancies. The EPFL spin-off’s technology targets preterm birth prevention by providing continuous, non-invasive monitoring of biochemical markers. When premature rupture of membranes occurs, the device aims to help clinicians quantify infection risk versus premature delivery complications. 🤰 👉 Full story: https://lnkd.in/gfUfVkZK #femtech #womenshealth #womenshealthinnovation #maternalhealth #pregancy #wearable #biomarker #novelbiomarker #funding #startup #medtech #medicaldevice

🤝 Maternal-fetal medicine telemedicine provider Ouma Health has acquired Sunny Day MFM and clinical assets of Boston MFM, adding four in-person care locations across Florida, Massachusetts and Maine. The acquisition expands Ouma’s service model beyond telemedicine to include hybrid care delivery. Founded in 2019, Ouma Health operates nearly 60 telemedicine sites supporting provider groups and health systems across the United States. The company partners with health systems, payors, OB groups, federally qualified health centers and employers to deliver maternal-fetal medicine services in all 50 states. 🤰 💬 “By building on our foundation as the nation’s premier teleMFM platform and expanding into hybrid care, we are creating a new standard of access and quality. This acquisition allows us to bring the best of both virtual and in-person care to communities that need it most.” Sina Haeri, MD, MHSA, Ouma Health CEO 👉 Full story: https://lnkd.in/gc4KfUDT #femtech #womenshealth #womenshealthinnovation #health #healthcare #digitalhealth #virtualcare #hybridcare #maternalhealth #infanthealth #pregnancy #acquisition #partnership

💰 LiviWell has closed a $3.3 million oversubscribed seed funding round to complete FDA clearance and launch Livi, a medical device designed to absorb semen and maintain vaginal pH balance after intercourse. The round was led by Atlantic Venture Studio, a subsidiary of ATLANTIC HEALTH SYSTEM (AHS) HOSPITAL CORPORATION. The company submitted Livi for FDA clearance in June 2025. ✅ 💬 “This funding represents more than capital—it’s a validation of our team’s dedication and the potential impact Livi can have on women’s sexual health and quality of life. With this support, we’re positioned to navigate the FDA clearance process and bring Livi to the women who need it most.” Dawn Halkuff, LiviWell CEO 👉 Full story: https://lnkd.in/gNRzVAeE #femtech #womenshealth #womenshealthinnovation #health #healthcare #sexualhealth #sexualwellness #vaginalhealth #regulatory #investment #startup

💰 Digital precision health platform Human Health has secured $8.5 million in funding to support international expansion and develop new research capabilities. The round included new investors LocalGlobe, Airtree, Skip Capital, ALIAVIA Ventures and Scale Investors. The company, co-founded in 2021 by former Canva product leaders Georgia V. and Kate Lambridis, previously raised $10.15 million in a 2022 seed round. Human Health has attracted more than 200,000 users worldwide who have logged 20 million health actions on the platform, with current daily usage exceeding 40,000 health actions. 📱 💬 "Right now, too many people are left in limbo; stuck on waiting lists, repeating their stories to different doctors, and trying to make sense of complex conditions without the right tools. Human Health is designed to change that." Human Health co-founder Kate Lambridis 👉 Full story: https://lnkd.in/gBYhiyXS #femtech #womenshealth #womenshealthinnovation #health #healthcare #healthtech #digitalhealth #investment #mobilehealth #app #funding #womenshealthresearch #startup #scaleup #investor #vc #venturecapital

✅ Spanish medtech company Innitius has received CE marking for CerviSense, an intravaginal probe and software platform that measures cervical stiffness to support clinical decisions in preterm birth management and labor induction. The certification enables commercial launch across Europe for the device, which provides operator-independent measurements of cervical tissue biomechanical properties. Clinical validation studies were conducted in Spain, the United Kingdom, and Germany prior to approval. 🇪🇺 💬 “This achievement marks a major step in our mission to bring better diagnostic tools to women’s health. We are now ready to bring CerviSense to market and expand access to a reliable, evidence-based assessment that has the potential to improve outcomes for mothers and babies.” Rubén Molina, Innitius CEO Full story: https://lnkd.in/gCR7Z_Np #femtech #womenshealth #womenshealthinnovation #health #healthcare #healthcareinnovation #healthtech #medtech #medicaldevice #maternalhealth #pregnancy #diagnostics #regulatory

🚀 Period tracking app Clue has become the first major cycle-tracking platform in the #UK to integrate prescription healthcare services, offering users free NHS-funded #contraception. The new feature addresses significant access barriers in the #UK, where nearly half of women struggle to obtain contraception and one in 20 patients wait at least four weeks for GP appointments. Clue worked with NHS-licensed healthcare platform Evaro to enable the integration. 💬 "Our mission at Clue is to help women and people with cycles understand their bodies and take control of their health. Our partnership with Evaro is another step on that journey and we are delighted to be rolling out this innovative and convenient solution that will provide women with better access to prescription medication and greater agency over their wellbeing." Rhiannon White, Clue CEO Full story: https://lnkd.in/geg9Z35q #femtech #womenshealth #womenshealthinnovation #digitalhealth #virtualcare #reproductivehealth #contraception #partnership #uk #launch #uk #unitedkingdom

✅ The U.S. Food and Drug Administration (FDA) has approved Bayer’s Lynkuet (elinzanetant) 60mg capsules for treating moderate to severe hot flashes in menopausal women, marking the first dual neurokinin receptor antagonist to enter the US market. The once-daily oral treatment works by blocking neurokinin 1 and neurokinin 3 receptors, targeting the brain’s temperature regulation system without using hormones. The approval follows positive results from three Phase III clinical trials involving over 1,400 women. 🔬 👉 Full story: https://lnkd.in/ggaM98bE #femtech #womenshealth #womenshealthinnovation #menopause #pharma #fda #regulatory #usa #unitedstarted #

🚀 U-Ploid Biotechnologies presented data from its first preclinical study of #Lyvanta (UP-085) at the American Society for Reproductive Medicine - ASRM annual meeting in San Antonio, showing the treatment reduced chromosomal separation errors in aged mouse eggs by 84.3%. The biotech company's therapeutic targets meiotic aneuploidy, which occurs when eggs develop with an incorrect number of chromosomes. This condition affects more than half of eggs in women over 33 and remains the primary cause of infertility and miscarriage in this age group. U-Ploid’s approach differs from existing fertility treatments by attempting to improve egg quality at the cellular level rather than selecting among existing eggs or embryos.🔬 💬 "Presenting our first Lyvanta data at ASRM marks a major milestone for U-Ploid. These findings represent a significant step towards translating our work into clinical applications that could improve fertility outcomes for women of advanced maternal age." Jordan Abdi, MD, U-Ploid Biotechnologies Co-founder & CEO 👉 Full story: https://lnkd.in/g_GNwYmh #femtech #womenshealth #womenshealthinnovation #health #healthcare #fertility #reproductivehealth #biotech #research #startup #uk #asrm #ivf

💰 knownwell has raised $25 million in an oversubscribed financing round led by CVS Health Ventures, bringing total funding to over $50 million. MassMutual Catalyst Fund, Intermountain Ventures, and others participated in the round, along with existing investors a16z Bio + Health and Flare Capital Partners. The Boston-based company provides obesity medicine and weight-inclusive primary care through a physician-led care model designed by co-founder and Chief Medical Officer Dr. Angela Fitch, Immediate Past President of the Obesity Medicine Association. 👇 💬 “Our model demonstrates that when you treat people with respect and deliver truly evidence-based obesity care, patients engage in unprecedented ways – delivering sustained and significant health improvements. Being backed by a leading payer is a powerful validation of that approach.” Brooke Boyarsky Pratt, Co-founder & CEO of knownwell 👉 Full story: https://lnkd.in/gbGbM3kg #health #healthcareinnovation #healthtech #healthcare #digitalhealth #hybridcare #primarycare #metabolichealth #obesity #weightcare #investment #investor #funding #startup #scaleup #boston